Perrigo Announces Approval for Rx Cetirizine Syrup

ALLEGAN, Mich., June 19 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq:
PRGO; TASE) today announced that it has received final approval from the U.S.
Food and Drug Administration to manufacture and market Cetirizine
Hydrochloride Syrup (Rx only), 1mg/mL. The product is comparable to McNeil
Consumer Healthcare's Zyrtec(R) Syrup, 1mg/mL, indicated for the relief of
symptoms associated with seasonal allergic rhinitis.
Perrigo's Chairman and CEO Joseph C. Papa stated, "This approval reflects
both our strategy to be first to market with important products and the unique
position of the Company both in front of and behind the pharmacy counter. This
product will join our line of Cetirizine tablets, Cetirizine D and Cetirizine
OTC syrup. Additionally, it contains active ingredient supplied by our own
API business, a continuation of our vertical integration efforts. This is yet
another example of how we are making quality healthcare more affordable for
consumers."
Perrigo Company is a leading global healthcare supplier that develops,
manufactures and distributes over-the-counter (OTC) and prescription
pharmaceuticals, nutritional products, active pharmaceutical ingredients (API)
and consumer products. The Company is the world's largest manufacturer of OTC
pharmaceutical products for the store brand market. The Company's primary
markets and locations of manufacturing facilities are the United States,
Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet
(http://www.perrigo.com).
Note: Certain statements in this press release are forward-looking
statements within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended, and are subject to the safe harbor created thereby. These
statements relate to future events or the Company's future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause the actual results, levels of activity, performance or
achievements of the Company or its industry to be materially different from
those expressed or implied by any forward-looking statements. In some cases,
forward-looking statements can be identified by terminology such as "may,"
"will," "could," "would," "should," "expect," "plan," "anticipate," "intend,"
"believe," "estimate," "predict," "potential" or other comparable terminology.
The Company has based these forward-looking statements on its current
expectations, assumptions, estimates and projections. While the Company
believes these expectations, assumptions, estimates and projections are
reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond the
Company's control. These and other important factors, including those
discussed under "Risk Factors" in the Company's Form 10-K for the year ended
June 30, 2007, as well as the Company's subsequent filings with the Securities
and Exchange Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these forward-looking
statements. The forward-looking statements in this press release are made
only as of the date hereof, and unless otherwise required by applicable
securities laws, the Company disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
SOURCE Perrigo Company

Arthur J. Shannon, Vice President, Investor Relations and Communication,
Perrigo Company, +1-269-686-1709, ajshannon@perrigo.com